Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATZUMI vs DIASTAT ACUDIAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.
Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults with PD-L1 expression ≥50%, with no EGFR or ALK genomic aberrations,First-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide,First-line treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic aberrations, in combination with bevacizumab, paclitaxel, and carboplatin,First-line treatment of metastatic squamous NSCLC in combination with paclitaxel and carboplatin,Treatment of locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy, or in cisplatin-ineligible patients with PD-L1 expression,Treatment of metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (d MMR) after prior fluoropyrimidine, oxaliplatin, and irinotecan therapy,Off-label uses: Various solid tumors with PD-L1 expression or MSI-H/d MMR
Status epilepticus,Acute repetitive seizures,Adjunctive treatment for epilepsy
1.2 g intravenously every 12 hours over 10-12 hours.
2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.
Terminal elimination half-life is 12-15 hours in patients with normal renal function (Cr Cl >90 m L/min), allowing once-daily dosing. Renal impairment prolongs half-life (up to 30 hours in Cr Cl 30-50 m L/min).
Terminal elimination half-life: 20-50 hours in adults; prolonged in elderly and patients with hepatic impairment (up to 100 hours).
Metabolized via catabolic pathways into small peptides and amino acids; not metabolized by cytochrome P450 enzymes.
Hepatic via CYP2C19, CYP3A4, and CYP2B6; major metabolite is N-desmethyldiazepam (active); also forms oxazepam and temazepam.
Approximately 70% of the dose is excreted renally as unchanged drug; 20% is eliminated via biliary/fecal routes as metabolites, with <5% as unchanged drug in feces.
Primarily renal (urinary) as glucuronide conjugates and unchanged drug; <2% excreted unchanged in feces.
95% bound to albumin and alpha-1-acid glycoprotein; binding is saturable at high concentrations.
97-99% bound primarily to albumin.
2.5-3.5 L/kg, indicating extensive extravascular distribution (e.g., tissues, erythrocytes).
0.8-1.4 L/kg (adults); reflects extensive distribution into tissues including brain.
Oral: 70-80% (first-pass metabolism reduces bioavailability; food increases absorption by 15%).
Rectal gel: 80-100% relative to intravenous administration.
Cr Cl 30-60 m L/min: 1.2 g every 18 hours; Cr Cl 10-29 m L/min: 1.2 g every 24 hours; Cr Cl <10 m L/min: 1.2 g loading dose then 0.6 g every 24 hours.
No specific dose adjustment provided in labeling; use with caution in severe renal impairment (Cr Cl < 10 m L/min) due to propylene glycol content.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Dose reduction may be necessary in Child-Pugh Class C cirrhosis; avoid in severe hepatic impairment due to decreased clearance and propylene glycol accumulation.
Not approved for pediatric patients under 18 years.
2 to 5 years: 0.5 mg/kg rectally; 6 to 11 years: 0.3 mg/kg; 12 years and older: 0.2 mg/kg. Dose per treatment episode not to exceed 20 mg.
No specific dose adjustment required; monitor renal function.
Start at lower end of dosing range (2.5-5 mg) due to increased sensitivity and decreased clearance; monitor for excessive sedation and respiratory depression.
None.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate response to alternatives.
Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin adverse reactions,Infusion-related reactions,Embryofetal toxicity,Increased risk of severe or fatal infection,Use caution in patients with autoimmune disease or organ transplant
Risk of respiratory depression, particularly with high doses or in elderly/chronically ill; tolerance and dependence; withdrawal symptoms; may impair cognitive and motor functions; should not be abruptly discontinued.
Severe hypersensitivity to atzumi or any excipients,Active severe autoimmune disease requiring systemic immunosuppression (relative),Pregnancy (embryofetal toxicity)
Hypersensitivity to diazepam or benzodiazepines; narrow-angle glaucoma; severe respiratory insufficiency; myasthenia gravis; concomitant use with opioids (except for palliative care).
Avoid alcohol consumption during therapy and for 48 hours after last dose due to risk of disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions known.
Grapefruit and grapefruit juice may increase diazepam levels and risk of toxicity; avoid concurrent consumption. Alcohol potentiates CNS depression and should be avoided. No other significant food interactions reported.
Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avoid unless benefit outweighs risk.
DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters, chronic use may lead to fetal benzodiazepine exposure; high doses near term can cause neonatal withdrawal (hypertonia, irritability, tremors, poor feeding) and 'floppy infant syndrome' (hypotonia, lethargy, respiratory depression). No known structural teratogenicity in later trimesters.
No data on excretion in human milk; M/P ratio unknown. Caution advised; use only if clearly needed.
Diazepam is excreted into breast milk; M/P ratio is approximately 0.1-0.3. Relative infant dose estimated at 1-10% of maternal weight-adjusted dose. Neonatal accumulation possible due to long half-life (50-100 hours in preterm neonates). Breastfeeding is not recommended during chronic use due to risks of sedation, poor feeding, and withdrawal. Short-term, single-dose use may be acceptable with monitoring.
No established dosing adjustments; pharmacokinetic changes in pregnancy may alter exposure. Monitor therapeutic response and adjust dose empirically based on clinical efficacy and toxicity.
Pregnancy increases volume of distribution and decreases albumin concentration, potentially reducing diazepam peak levels. However, drug clearance is unchanged or slightly decreased. Dose adjustments are individually determined based on clinical response; no fixed rule. Lower initial doses may be considered in third trimester due to enhanced drug sensitivity. After delivery, reduce dose to pre-pregnancy levels.
ATZUMI (aztreonam) is a monobactam antibiotic with activity against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. It is often used in patients with severe beta-lactam allergies (e.g., anaphylaxis to penicillins) due to minimal cross-reactivity. Monitor renal function (creatinine clearance) as dose adjustment is required in renal impairment. For cystic fibrosis patients, higher doses or continuous infusion may be considered. Administer over 20-60 minutes to reduce infusion-related phlebitis. Note: Inhaled aztreonam lysine (not ATZUMI) is used for chronic pulmonary infections in cystic fibrosis.
DIASTAT ACUDIAL is a diazepam rectal gel formulation used for acute repetitive seizures. Administer rectally; position patient on side to reduce aspiration risk. Do not administer more than 5 doses per month or more than 2 doses per single seizure episode. Monitor respiratory depression, especially with concurrent CNS depressants. Onset of action is 5-15 minutes; if seizure persists beyond 15 minutes, seek emergency medical attention. Avoid use in patients with acute narrow-angle glaucoma or severe liver disease.
Take this medication exactly as prescribed; do not skip doses or stop early unless instructed.,Report any signs of allergic reaction (rash, hives, itching, difficulty breathing, swelling of face/tongue) immediately.,Infusion site reactions (redness, swelling, pain) are common; notify healthcare provider if severe.,This drug may cause diarrhea, especially if prolonged; contact your doctor if watery or bloody stools occur.,Avoid alcohol while on this medication to reduce risk of disulfiram-like reaction (nausea, vomiting, headache).,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Complete full course even if you feel better to prevent antibiotic resistance.
Use exactly as prescribed; do not exceed recommended doses.,Insert the rectal gel tip gently and hold buttocks together for 1-2 minutes after administration.,Keep a seizure diary to track episodes and medication use.,Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while using this drug.,Seek medical help if seizures worsen or if breathing difficulties occur.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATZUMI vs DIASTAT ACUDIAL, answered by our medical review team.
ATZUMI is a Benzodiazepine Anticonvulsant that works by Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.. DIASTAT ACUDIAL is a Benzodiazepine Anticonvulsant that works by Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATZUMI and DIASTAT ACUDIAL depend on the specific clinical indication. These are both Benzodiazepine Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATZUMI is: 1.2 g intravenously every 12 hours over 10-12 hours.. The standard adult dose of DIASTAT ACUDIAL is: 2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATZUMI and DIASTAT ACUDIAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATZUMI is classified as Category C. Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avo. DIASTAT ACUDIAL is classified as Category C. DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.